Markers of endocrine neoplasia

Overview

Endocrine tumour biochemical markers span hormone products directly secreted by the tumour (functional markers, e.g. calcitonin for medullary thyroid carcinoma, catecholamine metabolites for phaeochromocytoma) and general tumour markers (e.g. chromogranin A) - functional markers are generally both more sensitive and more specific for their associated tumour type than general markers
Used across the range of endocrine neoplasia, from screening at-risk individuals (e.g. MEN2 gene carriers for medullary thyroid carcinoma) to diagnosis, staging, and treatment response monitoring in confirmed disease

Functional markers reflect direct tumour hormone secretion, making them highly specific when elevated in the correct clinical context, while general neuroendocrine markers (chromogranin A) reflect broader neuroendocrine cell activity and are more susceptible to non-tumour confounders (see )

Marker selection should match the specific suspected tumour type - e.g. calcitonin for medullary thyroid carcinoma, metanephrines/normetanephrines for phaeochromocytoma, specific hormone panels for functioning pancreatic neuroendocrine tumours - rather than a single generic "endocrine tumour marker" test applied uniformly
Genetic screening (e.g. RET proto-oncogene testing for MEN2, medullary thyroid carcinoma risk) complements biochemical marker testing in familial syndrome contexts

Elevated tumour-specific markers direct further localisation imaging and, in confirmed disease, guide surgical planning and serial monitoring for recurrence/treatment response
Genetic carriers of familial endocrine tumour syndromes (MEN1, MEN2) undergo structured biochemical surveillance programmes even before any tumour is clinically detected, aiming for pre-symptomatic diagnosis

Medullary thyroid carcinoma and calcitonin, phaeochromocytoma and metanephrines, MEN1/MEN2 biochemical surveillance programmes, functional vs general tumour marker specificity difference
Tumour-specific functional markers (calcitonin for medullary thyroid carcinoma, metanephrines for phaeochromocytoma) offer substantially better sensitivity and specificity than general neuroendocrine markers - marker selection should be matched to the specific suspected tumour type based on clinical context, not applied as an undifferentiated panel

4 more sections, plus exam facts

Premium unlocks every note across every specialty, and the full exam fact library behind it.